Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04322149 · ClinicalTrials.gov registry record · Phase 2
Multiple Doses of AT-1501-A201 in Adults With ALS
A Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Anelixis Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 13
- Study locations
NCT04322149: Completed Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Anelixis Therapeutics.
NCT04322149 is a Phase 2 study of Amyotrophic Lateral Sclerosis that has completed, run by Anelixis Therapeutics. The registered enrollment target is 54 participants, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (94% lower). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04322149, a Phase 2 study of Amyotrophic Lateral Sclerosis, has completed, sponsored by Anelixis Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40 ligand (CD40L). Approximately 54 adults with Amyotrophic Lateral Sclerosis (ALS) will be enrolled into the study in the United States and Canada at approximately 13 ALS treatment sites. Participants will be enrolled into one of four ascending doses.
Primary Outcome
Incidence of adverse events (AEs) reported as number of participants with at least one TEAE (Treatment Emergent Adverse Event) and at least one SAE (Serious Adverse Event).
Conditions Studied
Interventions
- DRUG AT-1501
Study Locations (13)
California
- University of California Irvine - Orange
- California Pacific Medical Center - San Francisco
Texas
- Texas Neurology, P.A. - Dallas
- Houston Methodist Neurological Institute - Houston
Arizona
- Barrows Neurological Institute - Phoenix
Georgia
- Augusta University - Augusta
Indiana
- University of Indiana - Indianapolis
Kansas
- The University of Kansas Medical Center - Kansas City
Maryland
- Johns Hopkins University Medical Center - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2020-10-16 |
| Est. Completion | 2022-03-24 |
| Phase | Phase 2 |
What the finished NCT04322149 record still lists
NCT04322149 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which AT-1501 is the first listed.
NCT04322149 lists 13 locations in 11 states (California, Texas, Arizona).
Frequently Asked Questions
What is clinical trial NCT04322149 about?
NCT04322149 is a clinical study titled "Multiple Doses of AT-1501-A201 in Adults With ALS". This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40 ligand (CD40L). Approximately 54 adults with Amyotrophic Lateral Sclerosis (ALS) will be enrolled into the study in the United States and Canada at approximately 13 ALS tr...
What is the current status of trial NCT04322149?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2020-10-16. Estimated completion is 2022-03-24.
What conditions does trial NCT04322149 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT04322149?
The interventions under investigation include: AT-1501 (DRUG).
Who is sponsoring clinical trial NCT04322149?
This trial is sponsored by Anelixis Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04322149 being conducted?
This trial has 13 study locations across Arizona, California, Georgia, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04322149's enrollment target sits among peer trials
54 53rd of 102 higher than 50 of 102 other Amyotrophic Lateral Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
RECRUITING · Phase 2
-
HEALEY ALS Platform Trial - Master Protocol
RECRUITING · Phase 2
-
RAPA-501 Therapy for ALS
RECRUITING · Phase 2
-
A Study of Ranolazine in ALS
RECRUITING · Phase 2
-
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI